SCHEMBL11965622

SCHEMBL11965622

COC1OC(CO)C(O)C(OC2OC(C(=O)O)C(C)C(O)C2O)C1NC(C)=O

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 7/20 0.49
▸ LGALS7; LGALS7B P47929 2/20 0.47
▸ LGALS1 P09382 1/20 0.47
▸ LGALS8 O00214 3/20 0.46
▸ LGALS4 P56470 1/20 0.46
▸ LGALS9 O00182 2/20 0.46
▸ MAPK1 P28482 2/20 0.44
▸ CD69 Q07108 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ PTN P21246 1/20 0.41
▸ MDK P21741 1/20 0.41
▸ BDNF P23560 1/20 0.41
▸ CHIA Q9BZP6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25768039 1.00 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
SCHEMBL17899826 0.90 BDNF (0.41) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL19184706 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL19846466 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL12691925 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL29360360 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL16311126 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL13472480 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL18232151 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
SCHEMBL19675783 0.89 MAPK1 (0.57) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389661-B2 Complexes between an amphiphilic polymer and an osteogenic protein belonging to the family of BMPs ADOCIA (FR) 2013-03-05 — — US disclosed
US-8241620-B2 Complex polymere amphiphile-PDGF ADOCIA (FR) 2012-08-14 — — US disclosed
US-20110301086-A1 Complex polymere amphiphile-PDGF ADOCIA (FR) 2011-12-08 — — US disclosed
US-20100190709-A1 Angiogenic composition ADOCIA (FR) 2010-07-29 — — US disclosed
US-20090221805-A1 Complex polymere amphiphile-PDGF PROTEINS AND PEPTIDES MANAGEMENT (FR) 2009-09-03 — — US disclosed
US-20090048412-A1 Complexes between an amphiphilic polymer and an osteogenic protein belonging to the family of BMPs ADOCIA (FR) 2009-02-19 — — US disclosed
US-20080293635-A1 Angiogenic composition ADOCIA (FR) 2008-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190709-A1 Angiogenic composition PDGFA, PGF, VEGFA LGALS3 745/4885LGALS7; LGALS7B 1816/4885LGALS1 961/4885
US-20110301086-A1 Complex polymere amphiphile-PDGF PDGFA, PDGFRA, FIBP LGALS3 1827/4885LGALS7; LGALS7B 2089/4885LGALS1 2072/4885
US-20090221805-A1 Complex polymere amphiphile-PDGF PDGFA, PDGFRA, FIBP LGALS3 1827/4885LGALS7; LGALS7B 2089/4885LGALS1 2072/4885
US-20080293635-A1 Angiogenic composition PDGFA, PGF, VEGFA LGALS3 745/4885LGALS7; LGALS7B 1816/4885LGALS1 961/4885
US-20090048412-A1 Complexes between an amphiphilic polymer and an osteogenic protein belonging to the family of BMPs BMP2, BMP1, BMP6 LGALS3 329/4885LGALS7; LGALS7B 372/4885LGALS1 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback